“Part D Compensation — 550% gains, nine years of monthly checks”
This one comes in from Stansberry and Associates, as an ad for Porter Stansberry’s Investment Advisory — if you subscribe, they’ll send you the special report: “Part D Compensation”— Monthly Checks for...
View ArticleFrom Rheumatism to RA: A Basic Change in Understanding
[ed note: Another piece from “Doc Gumshoe” today — Michael Jorrin is not a doctor, he’s a longtime medical writer who we love because he explains diseases, treatments, and health controversies in a way...
View ArticleThe Manchurian Candida
[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trading restrictions, and his words and opinions are his own. You can see his past articles and...
View ArticleTen Major Threats to Global Health According to the World Health Organization
Way back in April 2018, the World Health Organization issued its Thirteenth General Programme of Work, which attracted a certain amount of notice at the time, but was certainly not treated as...
View ArticleCombating Cancer: The Current Battle Plan
When we’re trying to fight against an adversary that is as strong and full of tricks as cancer, what we need to do is look for points of vulnerability – Achilles heels. We all remember, of course,...
View ArticleAlzheimer’s Disease: 2019 Refresher and Updates
From where I sit, it seems to me that the entire landscape of Alzheimer’s disease (AD) has changed, and changed quite significantly. The litany of announcements from pharmaceutical companies big and...
View ArticleWarm Bits for a Cold Month
Please indulge Doc Gumshoe while he presents his musings on what’s going on in general in the health-care arena, and in particular, which new drugs are getting the FDA blessing and why, as well as...
View ArticleCoronavirus Update – February 2020
Don’t look to Doc Gumshoe to keep you up to the minute on the spread of the Wuhan coronavirus. The figures I’m quoting below are as of mid-day today, February 18th. These will have changed by the...
View ArticleWyatt’s picks for “Coronavirus Biotech Boom?”
Ian Wyatt has been out over the past couple weeks with some “webinars” in which he talks up the coronavirus outbreak (for an hour!) and then ends his show with a tease about several “special reports”...
View ArticleDividend.com’s “Global Retailer With 40+ Years of Dividend Growth” Tease
During these crazy market moves, a lot of us are keeping in the back of our mind a notion along the lines of, “hey, this might be the chance to buy something cheap… but it better be really, really...
View Article58,300% Sales Surge for “Super Vaccine” Company?
Newsletters have taken to hiring spokespeople for their promo videos, trying to give them that extra flash of veritas and professionalism and a nice “anchor voice”, and this time it’s actress and...
View ArticleCOVID 19: What Are Prospects for the Duration?
The term “the duration” immediately recalls the Second World War. Nobody had any idea when it would be over, and so discussions of a lot of World War II-related events and conditions prominently...
View ArticleTwo more of Woods’“Guardian Angel” Stocks
Yesterday I spent some time on a pitch for a “Diamond in the Rough” stock from Jim Woods and promised to follow up… so that’s the plan this afternoon. The bigger theme of the ad was that Woods has a...
View ArticleCOVID Updates and October ’21 Miscellany
A friend of ours on the Maine island where we spent our vacation told us that her husband’s surgery had been cancelled at the last minute because the hospital in Portland was swamped with COVID cases,...
View ArticleCOVID-19: What Now?
Most of this Doc Gumshoe posting was ready to go a couple of days before Thanksgiving. But then, you know what happened: the new variant (now named Omicron) surfaced in South Africa. So I finished up...
View ArticleMarch 2022 Bulletins — Brief, but Relevant
On balance, these bits tend more to the positive than the negative, including a few positive items about COVID-19. (But then, it seems that most of the news about COVID-19 is on the positive side these...
View ArticleHarry Dent
Hi, I can’t find any new reviews in the Gummy on Harry Dent and his new crew of advisors. I am a long time subscriber to Dent’s stuff, my FA turned me onto to him in the 90’s, but sometimes I feel that...
View ArticleFollowing Up on Your Suggestions – September 2022
No surprise, the first comment to Doc Gumshoe’s piece on inflammation was this simple statement: “Next, I would like to read about anti-inflammatories.” It probably would have made sense to follow up...
View ArticleFriday File: More High Yield Speculation
We were pretty fortunate to catch the preferred shares of DigitalBridge (DBRG) at a good price about a month ago, and I’ve continued to poke around in the world of high-yield bonds and preferred...
View ArticleWyatt’s picks for “Coronavirus Biotech Boom?”
Ian Wyatt has been out over the past couple weeks with some “webinars” in which he talks up the coronavirus outbreak (for an hour!) and then ends his show with a tease about several “special reports”...
View Article